CDER Succession: Woodcock's Responsibilities Mount With No Clear #2 In Sight
Executive Summary
If FDA decides to replace Richard Moscicki, that individual will almost automatically be seen as Janet Woodcock’s heir-apparent at CDER, should she choose to retire.
You may also be interested in...
US FDA Taps Pfizer Executive For CDER Deputy Director Slot
Patrizia Cavazzoni, Janet Woodcock's new #2, has a background similar to Richard Moscicki, CDER's previous deputy director for operations.
Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
In memo to then-Commissioner Califf during review of Sarepta's Exondys 51, Jenkins wrote that he was concerned about leaving OND in hands of CDER director upon his retirement.
Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director
Peter Stein, a leader in diabetes drug development programs, joins FDA as a new administration is about to come in; he fills one of 676 CDER vacancies.